Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Flotetuzumab · MGD-006, RES-234

Bispecific antibody · Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 complex (CD3E) · developed by MacroGenics

Phase 2 Most advanced trial (none active)
MGNX Developer
2 Registered trials

What is Flotetuzumab?

Flotetuzumab is a humanized bispecific antibody built as a DART molecule, binding CD123 on tumor cells and CD3 on T cells. By crosslinking cytotoxic T lymphocytes to CD123-expressing cells, it is designed to drive T-cell-mediated lysis of those cells. It is studied in acute myeloid leukemia, including relapsed disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MGD-006, RES-234
Drug type
Bispecific antibody
Targets
CD123 (interleukin-3 receptor alpha chain) (IL3RA), CD3 complex (CD3E)
Mechanism
Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 complex (CD3E)
Pathways
T-cell mediated cytotoxicity, CTL-mediated lysis of tumor cells
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
0AHT0IC02G

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04582864 Phase 2 Relapsed Acute Myeloid Leukemia Terminated MGNX
NCT02152956 Phase 1/2 AML Terminated MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AMLRelapsed Acute Myeloid Leukemia

Other drugs acting on IL3RA / CD3E

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind Flotetuzumab

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.